Reyes Amanda, Muddasani Ramya, Massarelli Erminia
Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
Cancers (Basel). 2024 Aug 22;16(16):2919. doi: 10.3390/cancers16162919.
Lung cancer continues to contribute to the highest percentage of cancer-related deaths worldwide. Advancements in the treatment of non-small cell lung cancer like immune checkpoint inhibitors have dramatically improved survival and long-term disease response, even in curative and perioperative settings. Unfortunately, resistance develops either as an initial response to treatment or more commonly as a progression after the initial response. Several modalities have been utilized to combat this. This review will focus on the various combination treatments with immune checkpoint inhibitors including the addition of chemotherapy, various immunotherapies, radiation, antibody-drug conjugates, bispecific antibodies, neoantigen vaccines, and tumor-infiltrating lymphocytes. We discuss the status of these agents when used in combination with immune checkpoint inhibitors with an emphasis on lung cancer. The early toxicity signals, tolerability, and feasibility of implementation are also reviewed. We conclude with a discussion of the next steps in treatment.
肺癌在全球癌症相关死亡中所占比例仍然最高。免疫检查点抑制剂等非小细胞肺癌治疗方法的进步显著提高了生存率和长期疾病反应，即使在根治性和围手术期也是如此。不幸的是，耐药性要么作为对治疗的初始反应出现，要么更常见的是在初始反应后病情进展时出现。已经采用了几种方法来应对这一问题。本综述将重点关注免疫检查点抑制剂的各种联合治疗，包括添加化疗、各种免疫疗法、放疗、抗体药物偶联物、双特异性抗体、新抗原疫苗和肿瘤浸润淋巴细胞。我们讨论了这些药物与免疫检查点抑制剂联合使用时的情况，重点是肺癌。还回顾了早期毒性信号、耐受性和实施的可行性。我们最后讨论了治疗的下一步措施。
